摘要
目的探讨他克莫司替代治疗环孢素A不耐受的非重型再生障碍性贫血的临床效果.方法回顾性分析2017年1月~2018年2月我院收治的60例环孢素A不耐受的非重型再生障碍性贫血患者临床资料,依据疗效的不同分为治疗A组(20例)和治疗B组(40例),A组环孢素A无效换用他克莫司有效,B组环孢素A有效换用他克莫司仍有效.比较两组患者替换前后的血红蛋白、白细胞和血小板水平及60例患者替换前后的不良反应发生情况.结果两组患者替换前后的血红蛋白、白细胞和血小板水平比较,差异无统计学意义(P>0.05);两组患者替换后的血红蛋白、白细胞和血小板水平均高于替换前,差异有统计学意义(P<0.05).60例患者替换后的肾功能损伤、神经功能损伤、牙龈增生发生率均低于替换前,差异有统计学意义(P<0.05);60例患者替换前后的肝功能损伤、胃肠道反应发生率比较,差异无统计学意义(P>0.05).结论他克莫司替代治疗环孢素A不耐受的非重型再生障碍性贫血患者,临床效果更好,不良反应相对较少,值得临床推广应用.
Objective To explore the clinical effect of Tacrolimus replacement therapy for non-severe aplastic anemia with Cyclosporine A intolerance. Methods The clinical data of 60 patients with non-severe aplastic anemia with Cyclosporine A intolerance admitted to our hospital from January 2017 to February 2018 were retrospectively analyzed, they were divided into treatment group A (20 cases) and treatment group B (40 cases) according to different therapeutic effects. In group A, Tacrolimus was effective when Cyclosporine A was ineffective, but in group B, Tacrolimus was still effective when Cyclosporine A was effective. The levels of hemoglobin, leukocyte and platelet before and after replacement and the occurrence of adverse reactions in 60 patients before and after replacement were compared between the two groups. Results There were no significant differences in the levels of hemoglobin, white blood cells and platelets between the two groups before and after replacement (R>0.05). The levels of hemoglobin, leukocyte and platelet in the two groups after replacement were higher than those before replacement, the differences were statistically significant (P<0.05). The incidence of renal function injury, nerve function injury and gingival hyperplasia in 60 patients after replacement was lower than that before replacement, the differences were statistically significant (P<0.05). There was no significant differenee in the incidence of liver function injury and gastrointestinal reaction between 60 patients before and after replacement (P>0.05). Conclusion Tacrolimus replacement therapy for non-severe aplastic anemia patients with Cyclosporine A intolerance has better clinical effect and fewer adverse reactions, which is worthy of clinical application.
作者
李业锦
LI Ye-jin(Department of Internal Medicine of Hematology, Xinyi People's Hospital, Guangdong Province, Xinyi 525300, China)
出处
《中国当代医药》
2019年第15期87-89,共3页
China Modern Medicine
